Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2966811 | 1.00 | LMNA (0.73) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL30760509 | 0.86 | LMNA (0.57) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL10547816 | 0.84 | LMNA (0.55) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL30760453 | 0.81 | LMNA (0.51) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL11710533 | 0.81 | MEN1 (0.56) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL5935004 | 0.81 | LMNA (0.51) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL24793061 | 0.80 | LMNA (0.50) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL24793060 | 0.80 | LMNA (0.50) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL4799669 | 0.80 | ALDH1A1 (0.69) | LMNAKDM4EUSP2ALDH1A1POLB | |
| SCHEMBL4420917 | 0.79 | LMNA (0.49) | LMNAALDH1A1POLBL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928225-B2 | Oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2011-04-19 | — | — | US | disclosed |
| US-20100160626-A1 | Process For The Preparation Of 3,7-Dihydroxy-1,5-Diazacyclooctanes | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | LMNA 904/4885KDM4E 3729/4885USP2 4320/4885 |
| US-20100160626-A1 | Process For The Preparation Of 3,7-Dihydroxy-1,5-Diazacyclooctanes | CYP2D6, KCNH1, CYP2B6 | LMNA 502/4885KDM4E 1811/4885USP2 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.